A Phase 1 Trial of SL-801, a Novel Inhibitor of XPO1 Nuclear Export, in Patients With Advanced Solid Tumors

Trial Profile

A Phase 1 Trial of SL-801, a Novel Inhibitor of XPO1 Nuclear Export, in Patients With Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Jul 2017

At a glance

  • Drugs SL 801 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Stemline Therapeutics
  • Most Recent Events

    • 10 May 2017 According to a Stemline Therapeutics media release, the company has recently opened the sixth dosing cohort in this trial.
    • 21 Feb 2017 According to a Stemline Therapeutics media release, four dosing cohorts have been completed and enrollment in the fifth cohort is ongoing. Updates are expected later this year.
    • 03 May 2016 According to a Stemline Therapeutics media release, the company has completed the initial dosing cohort in this trial. The second cohort is currently open.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top